Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADA-011 Monotherapy and Combination in Advanced Solid Tumors
NCT05601219Phase 1Terminated
- Sponsor
- Adanate
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADA-011 in solid tumor (advanced stage) (3 arms), sponsored by Adanate. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) at 36 months and Number of Dose-Limiting Toxicities (DLTs) at 21 days. Started Nov 2022; status: terminated.
02
Drugs
ADA-011
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05601219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601219.